The IMA Group (IMA) has acquired multi-therapeutic company Clinical Trials of America (CTA) in the US.
This acquisition will bring four new independent locations and six embedded sites in Louisiana and North Carolina to IMA.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
CTA’s existing leadership, investigators, and staff will remain in place, led by its former CEO and president Jeb Andrews, and the company will continue its operations.
The IMA Group president and CEO Dr Mark Weinberger said: “The addition of CTA is a natural fit for our organisation, expanding our clinical network and adding a large, scalable research business that further differentiates us to sponsors and contract research organisations (CRO) for fast startup, quick enrolment, and high-quality outcomes.
“Our clinical research division has grown more than 300% during the past three years. CTA’s integrated physician practice research model and focus on recruiting diverse patients ideally fits with IMA Clinical Research’s vision and growth trajectory.”
CTA has therapeutic expertise in gastroenterology, cardiology, dermatology, vaccines, family medicine, and psychiatry.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWith this expertise of the company, the transaction further extends IMA Clinical Research’s reach in the Southeast.
The transaction also delivers productivity platforms, enabled by the technology and central services model of IMA, to more physicians’ offices.
New research capabilities of the company will also help expedite startup and the recruitment of participants while providing a wide range of trial opportunities to more patients.
Patients will get trial opportunities for additional disease states including hypertension, nonalcoholic steatohepatitis (NASH), atrial fibrillation, asthma, and smoking cessation.
Joining the IMA Clinical Research team as Operations senior regional director, Andrews will continue to lead the CTA sites and serve as a sub-investigator.
For this division, he will also assist with the development of new study sites and principal investigator onboarding.
The companies have not disclosed the terms of the transaction.
